New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
By Lauren Neves | September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...
Read More
Saving kids and dogs from shared cancers
By Guest Contributor | September 17, 2018
Ulrike Szalay is the Founder and Executive Director of Canines-N-Kids Foundation Did you know? Dogs and children spontaneously develop a number of similar cancers. In fact, cancer is the leading...
Read More
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
By Juliet Johnson | September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines. These...
Read More
New report details the setbacks and challenges to Alzheimer’s research
By Gretta Stone | September 12, 2018
Illustrating the challenges of developing medicines to fight Alzheimer’s disease, a new analysis found that between 1998 and 2017, there were 146 unsuccessful medicines in clinical trials for...
Read More
Disrupting Alzheimer's
By Andrew Powaleny | September 10, 2018
We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been...
Read More
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
By Guest Contributor | September 6, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New study finds some hospitals mark up medicine prices at least 700 percent
By Holly Campbell | September 5, 2018
A new analysis from The Moran Company found nearly one in five hospitals marks up medicine prices 700 percent or more. With this 700 percent markup, a $150 medicine purchased by a hospital could...
Read More
A call to action on Overdose Awareness Day
By Guest Contributor | August 31, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
By Guest Contributor | August 29, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH. ...
Read More
Number of value-based contracts continues to rise
By Michelle Drozd | August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
